📣 VC round data is live. Check it out!

Benitec Biopharma Valuation Multiples

Discover revenue and EBITDA valuation multiples for Benitec Biopharma and similar public comparables like Autolus Therapeutics, TaiMed Biologics, CytoDyn, Nika Pharmaceuticals and more.

Benitec Biopharma Overview

About Benitec Biopharma

Benitec Biopharma Inc is a clinical-stage biotechnology company focused on the advancement of novel genetic medicines. Its technology has the potential to provide a one-shot cure for a wide range of diseases that are addressed by strict ongoing treatment regimens or that have no effective treatment or only palliative care options. The Company is developing a silence and replace-based therapeutic (BB-301) for the treatment of Oculopharyngeal Muscular Dystrophy (OPMD), a chronic, life threatening genetic disorder.


Founded

2019

HQ

United States

Employees

19

Financials (LTM)

Revenue:
Net Income: ($46M)

EV

$231M

Valuation Multiples

Start free trial

Valuation Multiples for 15K+ Public Comps

AdidasAirbnbAmazonCiscoCoca-ColaDellDropboxIBMIntelMcDonaldsNikeNVIDIASamsungSpotifyTeslaToyota
Browse Valuation Multiples

Benitec Biopharma Financials

Benitec Biopharma reported last 12-month revenue of —.

In the same LTM period, Benitec Biopharma generated had net loss of ($46M).

Revenue (LTM)


Benitec Biopharma P&L

In the most recent fiscal year, Benitec Biopharma reported revenue of and EBITDA of ($41M).

Benitec Biopharma is unprofitable as of last fiscal year, with EBITDA margin of — and net margin of —.

See analyst estimates for Benitec Biopharma
LTMLast FY202320242025202620272028
Revenue$38K
EBITDA($41M)($21M)($32M)($41M)
EBITDA Margin(55060%)
EBIT Margin(55428%)
Net Profit($46M)($38M)($21M)($30M)($38M)
Net Margin(55084%)

Financial data powered by Morningstar, Inc.

Benitec Biopharma Stock Performance

Benitec Biopharma has current market cap of $418M, and enterprise value of $231M.

Market Cap Evolution


Benitec Biopharma's stock price is $12.18.

Benitec Biopharma share price increased by 1.3% in the last 30 days, and decreased by 20.7% in the last year.

Benitec Biopharma has an EPS (earnings per share) of $-1.10.

See more trading valuation data for Benitec Biopharma
EVMarket CapPrice 1DPrice 1MPrice 3MPrice 12MEPS
$231M$418M1.9%1.3%11.7%-20.7%$-1.10

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.

Start Free Trial

Benitec Biopharma Valuation Multiples

Benitec Biopharma trades at (5.6x) EV/EBITDA.

See NTM and 2027E valuation multiples for Benitec Biopharma

EV / Revenue (LTM)


Benitec Biopharma Financial Valuation Multiples

As of May 5, 2026, Benitec Biopharma has market cap of $418M and EV of $231M.

Benitec Biopharma has a P/E ratio of (9.2x).

LTMLast FY202320242025202620272028
EV/Revenuen/m
EV/EBITDA(5.6x)(11.2x)(7.3x)(5.6x)
EV/EBIT(4.6x)(5.5x)(11.1x)(7.2x)(5.5x)
P/E(9.2x)(11.0x)(20.3x)(14.0x)(11.0x)
EV/FCF(9.8x)(12.3x)(10.7x)(9.8x)

Multiples above and below 250x are considered non-meaningful (n/m). Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Verified Benitec Biopharma Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.

FactSetMorningstar
Start Free Trial

Benitec Biopharma Margins & Growth Rates

See estimated margins and future growth rates for Benitec Biopharma

Benitec Biopharma Growth Rates

23/2424/2526/2727/2828/29
Revenue Growth(100%)
EBITDA Growth54%30%
EBIT Growth55%30%
Net Profit Growth44%27%
FCF Growth15%9%

Data powered by FactSet, Inc. and Morningstar, Inc.

Benitec Biopharma Operational KPIs

Benitec Biopharma's revenue per employee in the last FY averaged $0.0M, while opex per employee averaged $2.2M for the same period.

Access forward-looking KPIs for Benitec Biopharma
Last FY2023202620272028
Revenue per Employee$0.0M
Opex per Employee$2.2M
G&A Expenses to Revenue17828%
R&D Expenses to Revenue37844%
Opex to Revenue55528%

Data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 230+ Verticals

Benitec Biopharma Competitors

Benitec Biopharma competitors include Autolus Therapeutics, TaiMed Biologics, CytoDyn, Nika Pharmaceuticals, Neumora Therapeutics, Recbio, Invivyd, Enanta Pharmaceuticals, Century Therapeutics and Cabaletta Bio.

Most Benitec Biopharma public comparables operate across Biopharmaceuticals, BioTech and DeepTech.

EV/RevenueEV/EBITDA
Last FYLTM2027ELast FYLTM2027E
Autolus Therapeutics2.5x2.0x(0.8x)(0.8x)
TaiMed Biologics19.4x18.9x(3435.1x)
CytoDyn49.8x
Nika Pharmaceuticals(5512.1x)
Neumora Therapeutics(1.3x)(1.4x)
Recbio245.0x247.2x(6.5x)
Invivyd3.6x3.0x(3.6x)(2.8x)
Enanta Pharmaceuticals4.5x4.4x(4.1x)(5.0x)

This data is available for Pro users. Sign up to see all Benitec Biopharma competitors and their valuation data.

Start Free Trial

Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples

Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.

Start Free Trial

About Benitec Biopharma

When was Benitec Biopharma founded?Benitec Biopharma was founded in 2019.
Where is Benitec Biopharma headquartered?Benitec Biopharma is headquartered in United States.
How many employees does Benitec Biopharma have?As of today, Benitec Biopharma has over 19 employees.
Who is the CEO of Benitec Biopharma?Benitec Biopharma's CEO is Jerel A. Banks.
Is Benitec Biopharma publicly listed?Yes, Benitec Biopharma is a public company listed on Nasdaq.
What is the stock symbol of Benitec Biopharma?Benitec Biopharma trades under BNTC ticker.
When did Benitec Biopharma go public?Benitec Biopharma went public in 2012.
Who are competitors of Benitec Biopharma?Benitec Biopharma main competitors include Autolus Therapeutics, TaiMed Biologics, CytoDyn, Nika Pharmaceuticals, Neumora Therapeutics, Recbio, Invivyd, Enanta Pharmaceuticals, Century Therapeutics, Cabaletta Bio.
What is the current market cap of Benitec Biopharma?Benitec Biopharma's current market cap is $418M.
Is Benitec Biopharma profitable?No, Benitec Biopharma is not profitable.
What is the current net income of Benitec Biopharma?Benitec Biopharma's last 12 months net income is ($46M).
How many companies Benitec Biopharma has acquired to date?Benitec Biopharma hasn't acquired any companies yet (or none have been disclosed publicly).
In how many companies Benitec Biopharma has invested to date?Benitec Biopharma hasn't invested in any companies yet (or none have been disclosed publicly).

See public comps similar to Benitec Biopharma

Lists including Benitec Biopharma

Start Your
Free Trial Today

Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.

Start Trial